Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Protalix BioTherapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:PBDA's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.64 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Protalix BioTherapeutics 5-Year Yield-on-Cost % Related Terms
FRA:PBDA vs GLSI, DTIL, NERV: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Protalix BioTherapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protalix BioTherapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Protalix BioTherapeutics's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Protalix BioTherapeutics (FRA:PBDA) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 19, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Protalix BioTherapeutics and its competitors. According to the industry distribution chart, Protalix BioTherapeutics ranks #999999 out of 149 companies in the Biotechnology industry.
Is Protalix BioTherapeutics' 5-Year Yield-on-Cost % too high?
Protalix BioTherapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Protalix BioTherapeutics ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Protalix BioTherapeutics has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' 5-Year Yield-on-Cost % compare to GLSI and DTIL?
According to the Biotechnology industry distribution chart, Protalix BioTherapeutics ranks #999999 out of 149 companies for 5-Year Yield-on-Cost %. This places Protalix BioTherapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.64, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Protalix BioTherapeutics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protalix BioTherapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (FRA:PBDA) is currently considered Fairly Valued. The stock's GF Value™ is €1.89, compared to a current price of €2.00 — trading 5.8% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Protalix BioTherapeutics' overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Protalix BioTherapeutics (FRA:PBDA), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protalix BioTherapeutics (FRA:PBDA) Overvalued in 2026?
Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued.
The current stock price of €2.00 is trading 5.8% above its estimated GF Value™ of €1.89.
GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.
Key valuation signals for FRA:PBDA:
5-Year Yield-on-Cost %: 0.00
GF Value™: €1.89 vs. price of €2.00 (5.8% above fair value)
No single metric tells the full story. See the FRA:PBDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
56GF Score
Get the complete analysis for FRA:PBDA
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PBDA has been successfully added to your 
